{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:00:26Z","timestamp":1794362426828,"version":"4.9.0"},"reference-count":62,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["DK046335"],"award-info":[{"award-number":["DK046335"]}]},{"name":"American Heart Association Predoctoral fellowship and Ellen Browning Scripps Foundation","award":["DK046335"],"award-info":[{"award-number":["DK046335"]}]},{"name":"Ellen Browning Scripps Foundation","award":["DK046335"],"award-info":[{"award-number":["DK046335"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Transthyretin (TTR) variant (V30M) polyneuropathy (ATTRv-PN) is a progressive systemic amyloidosis caused by transthyretin aggregation, leading to a variety of debilitating manifestations, including neuropathy and cardiomyopathy. We investigated the plasma proteome of heterozygotic V30M TTR asymptomatic carriers and heterozygotic V30M ATTRv-PN patients (before and after tafamidis treatment) versus WT TTR healthy control plasma using an organic solvent-induced shift in solubility assay to identify biosignatures for disease progression and therapeutic response. We identified many proteins, including TTR, apolipoproteins, ceruloplasmin, and proteins with functions in innate immunity that displayed changes in either their abundances or their sensitivity to precipitation. Elevated oxidative modifications of TTR and APOE in ATTRv-PN patients suggest a role for oxidative stress in disease pathogenesis\/progression. Tafamidis treatment mitigated these pathology-associated changes, suggesting that alleviating proteotoxic stress impacts these other pathways. Although our study was limited to a Portuguese cohort, these findings nevertheless provide a comprehensive plasma proteomic profile of V30M ATTRv-PN patients, V30M TTR carriers, and tafamidis-treated ATTRv-PN patients over up to 60 months; provide insights into ATTRv-PN pathophysiology; identify potential biomarkers for disease progression and therapeutic response; and highlight the utility of proteomics in advancing personalized treatments for amyloidosis.<\/jats:p>","DOI":"10.3390\/ijms26125534","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:11:49Z","timestamp":1749532309000},"page":"5534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Plasma Proteome Profiling Reveals Inflammation Markers and Tafamidis Effects in V30M Transthyretin Polyneuropathy"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1361-993X","authenticated-orcid":false,"given":"Karina","family":"Nugroho","sequence":"first","affiliation":[{"name":"Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-yon","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Coelho","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio Santo Ant\u00f3nio, 4050-342 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1178-1642","authenticated-orcid":false,"given":"James J.","family":"Moresco","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-8011","authenticated-orcid":false,"given":"Antonio F. M.","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-8487","authenticated-orcid":false,"given":"Evan T.","family":"Powers","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John R.","family":"Yates","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene K.","family":"Diedrich","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery W.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA"},{"name":"The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Poli, L., Labella, B., Cotti Piccinelli, S., Caria, F., Risi, B., Damioli, S., Padovani, A., and Filosto, M. (2023). Hereditary transthyretin amyloidosis: A comprehensive review with a focus on peripheral neuropathy. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1242815"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.1984.tb13742.x","article-title":"Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy","volume":"435","author":"Saraiva","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","article-title":"Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"10","author":"Wixner","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial","volume":"151","author":"Judge","year":"2024","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A Review of Patisiran (ONPATTRO(R)) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: A longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: A clinical and neurophysiological study","volume":"264","author":"Gorram","year":"2017","journal-title":"J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","article-title":"Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"7","author":"Mundayat","year":"2018","journal-title":"Neurol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e126526","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/13506129.2019.1575201","article-title":"Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: The role of randomized controlled trials","volume":"26","author":"Buxbaum","year":"2019","journal-title":"Amyloid"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Schonhoft, J.D., Monteiro, C., Plate, L., Eisele, Y.S., Kelly, J.M., Boland, D., Parker, C.G., Cravatt, B.F., Teruya, S., and Helmke, S. (2017). Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aam7621"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13506129.2022.2126308","article-title":"Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response","volume":"30","author":"Monteiro","year":"2023","journal-title":"Amyloid"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2016072118","DOI":"10.1073\/pnas.2016072118","article-title":"A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction","volume":"118","author":"Jiang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/13506129.2010.483118","article-title":"Serum transthyretin levels in Swedish TTR V30M carriers","volume":"17","author":"Buxbaum","year":"2010","journal-title":"Amyloid"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1110\/ps.8901","article-title":"Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins","volume":"10","author":"Schneider","year":"2001","journal-title":"Protein Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000153944","article-title":"Association of C3 and C4A complement types with familial amyloidotic polyneuropathy","volume":"40","author":"Nylander","year":"1990","journal-title":"Hum. Hered."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2009.05.018","article-title":"Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met","volume":"284","author":"Dardiotis","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1034\/j.1600-065X.2001.1800103.x","article-title":"Structure and biology of complement protein C3, a connecting link between innate and acquired immunity","volume":"180","author":"Sahu","year":"2001","journal-title":"Immunol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12500","article-title":"Complement component C3-The \u201cSwiss Army Knife\u201d of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer\u2019s disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/alz.12333","article-title":"Plasma amyloid beta levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants","volume":"17","author":"Damotte","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6024975","DOI":"10.1155\/2019\/6024975","article-title":"Oxidative Stress, Chronic Inflammation, and Amyloidoses","volume":"2019","author":"Orzechowski","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mas.20006","article-title":"Proteins as biomarkers of oxidative\/nitrosative stress in diseases: The contribution of redox proteomics","volume":"24","author":"Scaloni","year":"2005","journal-title":"Mass Spectrom. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"da Costa, G., Ribeiro-Silva, C., Ribeiro, R., Gilberto, S., Gomes, R.A., Ferreira, A., Mateus, E., Barroso, E., Coelho, A.V., and Freire, A.P. (2015). Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125392"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.injury.2007.04.019","article-title":"Blunt abdominal injury: Serum ALT\u2014A marker of liver injury and a guide to assessment of its severity","volume":"38","author":"Srivastava","year":"2007","journal-title":"Injury"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","article-title":"Plasma phospho-tau in Alzheimer\u2019s disease: Towards diagnostic and therapeutic trial applications","volume":"18","author":"Kac","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","article-title":"Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"L16","DOI":"10.1152\/ajplung.00044.2008","article-title":"Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs","volume":"295","author":"Gerszten","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/jasms.3c00182","article-title":"Differential Precipitation of Proteins: A Simple Protein Fractionation Strategy to Gain Biological Insights with Proteomics","volume":"34","author":"Pinto","year":"2023","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Xu, M., Moresco, J.J., Chang, M., Mukim, A., Smith, D., Diedrich, J.K., Yates, J.R., and Jones, K.A. (2018). SHMT2 and the BRCC36\/BRISC deubiquitinase regulate HIV-1 Tat K63-ubiquitylation and destruction by autophagy. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007071"},{"key":"ref_47","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2000). The Effect of Inflammation and Infection on Lipids and Lipoproteins. Endotext, MDText.com, Inc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1021\/acs.jproteome.7b00479","article-title":"Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm)","volume":"16","author":"Chan","year":"2017","journal-title":"J. Proteome Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Azevedo, E.P., Guimaraes-Costa, A.B., Bandeira-Melo, C., Chimelli, L., Waddington-Cruz, M., Saraiva, E.M., Palhano, F.L., and Foguel, D. (2019). Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1369-4"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/1570159X16666180508113025","article-title":"Does Ceruloplasmin Defend Against Neurodegenerative Diseases?","volume":"17","author":"Wang","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.nutr.22.012502.114457","article-title":"Ceruloplasmin metabolism and function","volume":"22","author":"Hellman","year":"2002","journal-title":"Annu. Rev. Nutr."},{"key":"ref_52","first-page":"223","article-title":"Severe hypocupremia and familial amyloid polyneuropathy","volume":"37","year":"2020","journal-title":"Nutr. Hosp."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ciccone, L., Fruchart-Gaillard, C., Mourier, G., Savko, M., Nencetti, S., Orlandini, E., Servent, D., Stura, E.A., and Shepard, W. (2018). Copper mediated amyloid-beta binding to Transthyretin. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-31808-5"},{"key":"ref_54","first-page":"83","article-title":"Associations of decreased serum transthyretin with elevated high-sensitivity CRP, serum copper and decreased hemoglobin in ambulatory elderly women","volume":"24","author":"Tsuboi","year":"2015","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.conb.2011.08.002","article-title":"Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer\u2019s disease","volume":"21","author":"Keene","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2147\/NDT.S84266","article-title":"Role of apolipoprotein E in neurodegenerative diseases","volume":"11","author":"Giau","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13024-022-00566-4","article-title":"APOE in the bullseye of neurodegenerative diseases: Impact of the APOE genotype in Alzheimer\u2019s disease pathology and brain diseases","volume":"17","author":"Konings","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1194\/jlr.R075408","article-title":"The role of APOE on lipid homeostasis and inflammation in normal brains","volume":"58","author":"Rebeck","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bartolacci, C., Andreani, C., El-Gammal, Y., and Scaglioni, P.P. (2021). Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.706650"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Endale, H.T., Tesfaye, W., and Mengstie, T.A. (2023). ROS induced lipid peroxidation and their role in ferroptosis. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1226044"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mas.21540","article-title":"The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics","volume":"39","author":"Pino","year":"2020","journal-title":"Mass Spectrom. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:49:15Z","timestamp":1760032155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26125534"],"URL":"https:\/\/doi.org\/10.3390\/ijms26125534","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}